Momelotinib, a oral medication taken once a day, improves the vital effects of patients treated for myelofibrosis (MF), a rare but deadly bone cancer, researchers reported June 7. Ruben Mesa, MD, FACP, executive director of the Mays Cancer Center. home to UT Health San Antonio MD Anderson Cancer Center, presented the results of the MOMENTUM phase 3 randomized study, which evaluated momelotinib on the second drug, danazol, in the symptoms and MF patients previously ill treated with a controlled JAK inhibitor.
Dr. Mesa, chief research officer, announced the findings in Chicago at the annual meeting of the American Association of Professional Engineers (ASCO). MOMENTUM registered 195 MF patients in 21 countries.
In myelofibrosis, a scar tissue is found inside bones and inhibits the body’s ability to produce healthy blood cells. Anemia, lack red blood cells to carry oxygen throughout the body, it is observed in almost all MF patients with adverse effects on life, says Dr. Mesa.
“Three-quarters of patients have anemia in the future, and most patients will develop it during the course of the disease,” said Dr. Mesa. “For patients with severe anemia, life expectancy is limited to about two years. Even with mild anemia, the median life expectancy is 4.9 years. Treatment is needed to treat anemia in these patients urgently.”
Without anemia, the average life expectancy with MF is almost eight years, he said.
Myelofibrosis is characterized by an abnormal signaling of the JAK protein and the overgrowth of another protein, ACVR1. The first MF drugs developed over the past decade, such as ruxolitinib, inhibit the harmful JAK signal, while momelotinib is the primary drug that inhibits both JAK and ACVR1, according to Dr. Mesa.
“It has inhibitors JAK1, JAK2 and ACVR1 in the same drug and address chronic inflammation due to the increase in ACVR1 as a result of the disease, ”said Dr. Mesa.
Of the registered participants, 130 received momelotinib and 65 danazol. Participants did not know until after 24 weeks which remedy received, and those in the danazol group were allowed to switch to momelotinib at the time.
In the group momelotinib:
- All prerequisites for primary and secondary key are fulfilled.
- Significant progress has been made in symptoms, splint size and levels of anemia.
- Improved safety and quality of life have been documented.
- Participants needed more blood transfusions to replace red blood cells and confirmed optimal levels of hemoglobin containing oxygen.
“The results have been impressive,” said Dr. Mesa. “The study put the participants in a complete coma during COVID, which was amazing. Momelotinib met all the primary and secondary levels and in a short period of six months, there was a significant improvement in the overall quality of life, which and it’s amazing. “
University of Texas Health Science Center in San Antonio
hint: Oral Surgery Improves Care for People With Bone Cancer: Review (2022, June 7) Retrieved 7 June 2022 from https://medicalxpress.com/news/2022-06-oral-pill-patients-bone -marrow.html
This document is copyrighted. Apart from any genuine transaction for the purpose of personal analysis or investigation, any part may not be reproduced without our written permission. Content is provided for informational purposes only.
Oral pill improves care of patients with bone marrow cancer: Study Source link Oral pill improves care of patients with bone marrow cancer: Study